Business
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).
About this update from Neurizon Therapeutics Limited
[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Study is expected to complete enrolment in H2 CY2026","length":52,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":600,"olType":false},{"type":"text","content":"MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).","length":506,"tagName":"p"},{"type":"text","content":"HEALEY ALS Platform Trial","length":25,"tagName":"p"},{"type":"text","content":"The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies. The trial evaluates multiple investigational drugs (Regimens) conc...